arGEN-X Raises €40 million in successful Initial Public Offering on Euronext Brussels

July 08, 2014

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (“arGEN-X”), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announces the successful completion of its Initial Public Offering, which was launched on 23 June 2014 (the “IPO” or the “Offering”). arGEN-X shares will be listed on Euronext Brussels and begin trading on an “if-and-when-issued-or-delivered” basis on Thursday 10 July 2014 under the symbol “ARGX”.